Impact Biomedicines CEO John Hood’s steadfast commitment to a drug that he co-invented translated into a deal with Celgene potentially worth $7 billion. Photo courtesy of Impact Biomedicines

— John Hood turned a cast-off drug into a multibillion deal...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to archives
  • Book of Lists — the most comprehensive business resource in San Diego
  • NEW: San Diego 500 — influential business leaders you need to know
Yours for only $129